Andre R Miserez
Overview
Explore the profile of Andre R Miserez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elshorbagy A, Vallejo-Vaz A, Barkas F, Lyons A, Stevens C, Dharmayat K, et al.
Eur Heart J
. 2025 Jan;
PMID: 39801189
Background And Aims: Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and...
2.
Katsiki N, Mikhailidis D, Bajraktari G, Miserez A, Cicero A, Bruckert E, et al.
Pharmacol Res
. 2020 Feb;
155:104719.
PMID: 32087236
Acute and chronic physical exercises may enhance the development of statin-related myopathy. In this context, the recent (2019) guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis...
3.
Wilemon K, Patel J, Aguilar-Salinas C, Ahmed C, Alkhnifsawi M, Almahmeed W, et al.
JAMA Cardiol
. 2020 Jan;
5(2):217-229.
PMID: 31895433
Importance: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder that leads to premature morbidity and mortality due to atherosclerotic cardiovascular disease. Familial hypercholesterolemia affects 1 in 200 to...
4.
Vallejo-Vaz A, De Marco M, Stevens C, Akram A, Freiberger T, Hovingh G, et al.
Atherosclerosis
. 2018 Oct;
277:234-255.
PMID: 30270054
Background And Aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the...
5.
Vallejo-Vaz A, Akram A, Seshasai S, Cole D, Watts G, Hovingh G, et al.
Atheroscler Suppl
. 2016 Dec;
22:1-32.
PMID: 27939304
Background: The potential for global collaborations to better inform public health policy regarding major non-communicable diseases has been successfully demonstrated by several large-scale international consortia. However, the true public health...
6.
Andersen L, Miserez A, Ahmad Z, Andersen R
J Clin Lipidol
. 2016 Dec;
10(6):1297-1302.
PMID: 27919345
Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant genetic disorder of lipid metabolism associated with hyperlipidemia and elevated risk for atherosclerosis. FDB is caused by mutations in APOB reducing...
7.
Andersen L, Andersen R, Miserez A
J Clin Lipidol
. 2016 Sep;
10(4):1050-1051.
PMID: 27578140
No abstract available.
8.
Arnold-Worner N, Goldblum D, Miserez A, Flammer J, Meyer P
Graefes Arch Clin Exp Ophthalmol
. 2012 Mar;
250(8):1241-3.
PMID: 22411127
No abstract available.
9.
Spiegel R, Berres M, Miserez A, Monsch A
Alzheimers Res Ther
. 2011 Mar;
3(2):9.
PMID: 21418632
Introduction: Novel compounds with potential to attenuate or stop the progression of Alzheimer's disease (AD) from its presymptomatic stage to dementia are being tested in man. The study design commonly...
10.
Weiss R, Otvos J, Sinnreich R, Miserez A, Kark J
J Pediatr
. 2010 Aug;
158(1):44-50.
PMID: 20801459
Objective: To assess whether the fasting triglyceride-to-high-density lipoprotein (HDL)-cholesterol (TG/HDL) ratio in adolescence is predictive of a proatherogenic lipid profile in adulthood. Study Design: A longitudinal follow-up of 770 Israeli...